What it's for (Indications)
- Methyltestosterone is indicated for testosterone replacement therapy in males for conditions associated with symptoms of deficiency or absence of endogenous testosterone.
- This includes primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired).
- Historically, it has also been used in the palliative treatment of metastatic mammary carcinoma in females who are one to five years postmenopausal, or as a secondary therapeutic agent in women with operable metastatic breast cancer.
- Its use for delayed puberty in males has also been documented.
- However, due to its significant hepatotoxicity and the availability of newer, safer testosterone formulations, its current clinical utility for hypogonadism is highly limited and often discouraged in favor of other preparations.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage of methyltestosterone must be individualized based on the patient's age, diagnosis, clinical response to therapy, and objective measures such as serum testosterone levels. For male hypogonadism, typical oral dosages generally range from 10 mg to 50 mg daily, administered orally. For the palliative treatment of metastatic mammary carcinoma in females, dosages historically ranged from 50 mg to 200 mg daily, often given in divided doses. The medication is exclusively administered orally. Clinical response, occurrence of adverse reactions, and laboratory parameters, including serum testosterone concentrations, hemoglobin, hematocrit, and liver function tests, should be regularly monitored to permit appropriate dose adjustments and ensure the lowest effective dose is consistently utilized. Long-term use necessitates careful and continuous medical supervision due to potential adverse effects. |
Safety & Warnings
Common Side Effects
- Common side effects associated with methyltestosterone therapy include, but are not limited to, dermatological manifestations such as acne, hirsutism (excessive hair growth), and male pattern baldness.
- Changes in libido are frequently reported.
- In male patients, potential side effects can encompass gynecomastia (breast enlargement), priapism (prolonged and often painful erections), and oligospermia (reduced sperm count) due to feedback inhibition of endogenous testosterone production.
- Females may experience virilization, characterized by irreversible voice deepening, clitoral enlargement, and menstrual irregularities.
- Fluid and electrolyte disturbances, such as edema, sodium retention, and hypercalcemia, can occur.
- Gastrointestinal disturbances are also possible.
- Of paramount concern is hepatic toxicity, which can manifest as elevated liver enzymes, cholestatic jaundice, peliosis hepatis (blood-filled cysts in the liver), and, rarely, hepatic neoplasms, particularly with prolonged use of 17-alpha-alkylated androgens like methyltestosterone.
- Psychiatric effects, including mood swings, irritability, aggression, and depression, have also been reported.
- Regular monitoring is essential to detect and manage these adverse effects promptly and prevent severe complications.
Serious Warnings
- Black Box Warning: **WARNING: HEPATIC TOXICITY, CARDIOVASCULAR AND THROMBOEMBOLIC EVENTS, AND ABUSE POTENTIAL.** **1. Hepatic Toxicity:** Methyltestosterone, a 17-alpha-alkylated androgen, has been associated with severe, life-threatening hepatotoxicity, including cholestatic hepatitis, hepatocellular necrosis, peliosis hepatis, and hepatic neoplasms (e.g., hepatocellular carcinoma), some of which have been fatal. These adverse hepatic effects can occur even at therapeutic doses and with short-term use. Liver function tests (e.g., AST, ALT, bilirubin) should be monitored regularly during therapy, and treatment should be discontinued immediately if liver enzyme elevations are significant or if symptoms of liver dysfunction (e.g., jaundice, dark urine, abdominal pain) occur. Due to this risk, its clinical utility is often limited. **2. Cardiovascular and Thromboembolic Events:** Androgens, including methyltestosterone, may increase the risk of serious cardiovascular events, including myocardial infarction (heart attack) and stroke. There have also been post-marketing reports of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients using testosterone products. Patients with pre-existing cardiac, renal, or hepatic disease, or those with other risk factors for cardiovascular disease, should be approached with extreme caution, and the risks versus benefits carefully weighed. **3. Abuse Potential:** Anabolic androgenic steroids (AAS), including methyltestosterone, are subject to abuse, typically at doses higher than those recommended for therapeutic purposes. Abuse of AAS, often in combination with other anabolic agents, is associated with serious adverse reactions across multiple organ systems, including severe cardiovascular events (e.g., myocardial infarction, heart failure, sudden death), hepatic dysfunction (e.g., cholestatic jaundice, hepatic neoplasms), and psychiatric manifestations (e.g., mood swings, aggression, depression, psychosis, delusions). Long-term abuse can lead to physical and psychological dependence, and withdrawal symptoms, including depression and fatigue, can occur upon abrupt cessation. Healthcare providers should assess patients for anabolic steroid abuse and educate them about the serious health risks associated with such abuse.
- Methyltestosterone, as a 17-alpha-alkylated androgen, carries significant warnings regarding its use.
- **Hepatic Toxicity:** This drug can cause severe, life-threatening liver damage, including cholestatic hepatitis, hepatocellular necrosis, peliosis hepatis, and hepatic neoplasms, even at therapeutic doses.
- Liver function tests must be monitored regularly, and treatment should be discontinued if liver enzyme elevations are significant or symptoms of liver dysfunction occur.
- **Cardiovascular Risk:** Androgens, including methyltestosterone, may increase the risk of myocardial infarction, stroke, and venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE).
- Patients with pre-existing cardiovascular disease should be closely monitored.
- **Prostate Effects:** Androgens can accelerate the growth of existing prostate cancer and benign prostatic hyperplasia (BPH).
- Regular prostate examinations and PSA measurements are strongly recommended for all men receiving testosterone therapy, especially those over 40 years of age.
- **Polycythemia:** Increases in hematocrit and hemoglobin levels require diligent monitoring due to the risk of polycythemia, which can further increase the risk of thrombotic events.
- **Fluid Retention:** Edema with or without congestive heart failure can occur, especially in patients with pre-existing cardiac, renal, or hepatic disease.
- **Abuse Potential:** Anabolic androgenic steroids are subject to abuse, often at doses higher than recommended, leading to serious adverse effects and potential dependence, requiring careful assessment by healthcare providers.
How it Works (Mechanism of Action)
Methyltestosterone is a synthetic, orally active androgen derived from testosterone. Its primary mechanism of action involves binding to specific high-affinity androgen receptors located within the cytoplasm of target cells in various tissues, including the prostate, seminal vesicles, epididymis, skeletal muscle, bone, and certain areas of the brain. Upon ligand binding, the activated hormone-receptor complex undergoes a conformational change and translocates into the cell nucleus, where it interacts with specific DNA sequences known as androgen response elements (AREs) located in the promoter regions of target genes. This interaction regulates gene transcription, leading to the synthesis of messenger RNA (mRNA) and, subsequently, specific proteins. These proteins mediate the characteristic androgenic effects, including the development and maintenance of primary and secondary male sexual characteristics, promotion of protein anabolism, stimulation of erythropoiesis, and influence on bone density. Methyltestosterone also undergoes some aromatization to methylestradiol, exhibiting minor estrogenic activity. The 17-alpha-alkylation modification grants it oral bioavailability by slowing its hepatic metabolism, but this structural feature also significantly contributes to its potential for hepatotoxicity.